PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Peking University Peoples Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, No.11, Xizhimen Nan Street, Beijing, 100044, China.\', \'JC School of Public Health and Primary Care, Chinese University of Hong Kong, Hong Kong SAR, China.\', \'Chinese Lymphoma Patients Organization, House086, Beijing, China.\', \'Haematology Research Centre, Department of Immunology and Inflammation, Imperial College London, London, UK.\', \'Harbin Institute of Hematology and Oncology, Harbin, China.\', \'Peking University Peoples Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, No.11, Xizhimen Nan Street, Beijing, 100044, China. huangxiaojun@bjmu.edu.cn.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1007/s00432-020-03426-0
?:hasPublicationType
?:journal
  • Journal of cancer research and clinical oncology
is ?:pmid of
?:pmid
?:pmid
  • 33078214
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.235
?:rankingScore_hIndex
  • 84
is ?:relation_isRelatedTo_publication of
?:title
  • Impact of stopping therapy during the SARS-CoV-2 pandemic in persons with lymphoma.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33078214>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33078214>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all